What is the expected CAGR for the Veterinary Infectious Disease Therapeutic Market from 2025 to 2035?

The expected CAGR for the Veterinary Infectious Disease Therapeutic Market during the forecast period 2025 - 2035 is 5.4%. Read More

Which therapeutic class is projected to have the highest valuation by 2035?

By 2035, vaccines are projected to have the highest valuation, increasing from 1.2 USD Billion in 2024 to 2.1 USD Billion. Read More

How do companion animals compare to livestock in terms of market valuation in 2035?

In 2035, companion animals are projected to reach a market valuation of 2.5 USD Billion, compared to livestock at 1.8 USD Billion. Read More

What are the projected valuations for bacterial infections by 2035?

The projected valuation for bacterial infections is expected to rise from 0.9 USD Billion in 2024 to 1.5 USD Billion by 2035. Read More

Which key players are leading the Veterinary Infectious Disease Therapeutic Market?

Key players in the market include Zoetis, Merck Animal Health, Boehringer Ingelheim, and Elanco Animal Health. Read More

What is the expected growth for antifungals in the Veterinary Infectious Disease Therapeutic Market?

Antifungals are projected to grow from 0.24 USD Billion in 2024 to 0.69 USD Billion by 2035. Read More

What route of administration is expected to dominate the market by 2035?

Both oral and injectable routes of administration are projected to dominate the market, each reaching 2.5 USD Billion by 2035. Read More

How does the market for parasitic infections compare to that of viral infections by 2035?

By 2035, the market for parasitic infections is projected to reach 1.5 USD Billion, while viral infections are expected to reach 2.0 USD Billion. Read More

Veterinary Infectious Disease Therapeutic Market

Q: What is the projected market valuation for the Veterinary Infectious Disease Therapeutic Market in 2035?

The projected market valuation for the Veterinary Infectious Disease Therapeutic Market in 2035 is 6.492 USD Billion. Read More

Q: What was the overall market valuation in 2024?

The overall market valuation for the Veterinary Infectious Disease Therapeutic Market was 3.64 USD Billion in 2024. Read More

Veterinary Infectious Disease Therapeutic Market Research Report: Size, Share, Trend Analysis By Applications (Bacterial Infections, Viral Infections, Fungal Infections, Parasitic Infections), By Animal Type (Companion Animals, Livestock, Pets, Equine), By Therapeutic Class (Antibiotics, Vaccines, Antiparasitics, Antifungals), By Route of Administration (Oral, Injectable, Topical) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

5.4%

2024 Market Size

$ 3.64 Billion

2035 Market Size

$ 6.49 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/40629-HCR | Pages: 200 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Application (USD Billion) | |
  1. 4.1.1 Bacterial Infections | |
  2. 4.1.2 Viral Infections | |
  3. 4.1.3 Fungal Infections | |
  4. 4.1.4 Parasitic Infections |
2. 4.2 Healthcare, BY Animal Type (USD Billion) | |
  1. 4.2.1 Companion Animals | |
  2. 4.2.2 Livestock | |
  3. 4.2.3 Pets | |
  4. 4.2.4 Equine |
3. 4.3 Healthcare, BY Therapeutic Class (USD Billion) | |
  1. 4.3.1 Antibiotics | |
  2. 4.3.2 Vaccines | |
  3. 4.3.3 Antiparasitics | |
  4. 4.3.4 Antifungals |
4. 4.4 Healthcare, BY Route of Administration (USD Billion) | |
  1. 4.4.1 Oral | |
  2. 4.4.2 Injectable | |
  3. 4.4.3 Topical |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Zoetis (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Merck Animal Health (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Boehringer Ingelheim (DE) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Elanco Animal Health (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Virbac (FR) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Ceva Santé Animale (FR) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Vetoquinol (FR) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Heska Corporation (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Phibro Animal Health (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY APPLICATION |
7. 6.4 US MARKET ANALYSIS BY ANIMAL TYPE |
8. 6.5 US MARKET ANALYSIS BY THERAPEUTIC CLASS |
9. 6.6 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
10. 6.7 CANADA MARKET ANALYSIS BY APPLICATION |
11. 6.8 CANADA MARKET ANALYSIS BY ANIMAL TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY THERAPEUTIC CLASS |
13. 6.10 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY APPLICATION |
16. 6.13 GERMANY MARKET ANALYSIS BY ANIMAL TYPE |
17. 6.14 GERMANY MARKET ANALYSIS BY THERAPEUTIC CLASS |
18. 6.15 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
19. 6.16 UK MARKET ANALYSIS BY APPLICATION |
20. 6.17 UK MARKET ANALYSIS BY ANIMAL TYPE |
21. 6.18 UK MARKET ANALYSIS BY THERAPEUTIC CLASS |
22. 6.19 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
23. 6.20 FRANCE MARKET ANALYSIS BY APPLICATION |
24. 6.21 FRANCE MARKET ANALYSIS BY ANIMAL TYPE |
25. 6.22 FRANCE MARKET ANALYSIS BY THERAPEUTIC CLASS |
26. 6.23 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
27. 6.24 RUSSIA MARKET ANALYSIS BY APPLICATION |
28. 6.25 RUSSIA MARKET ANALYSIS BY ANIMAL TYPE |
29. 6.26 RUSSIA MARKET ANALYSIS BY THERAPEUTIC CLASS |
30. 6.27 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
31. 6.28 ITALY MARKET ANALYSIS BY APPLICATION |
32. 6.29 ITALY MARKET ANALYSIS BY ANIMAL TYPE |
33. 6.30 ITALY MARKET ANALYSIS BY THERAPEUTIC CLASS |
34. 6.31 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
35. 6.32 SPAIN MARKET ANALYSIS BY APPLICATION |
36. 6.33 SPAIN MARKET ANALYSIS BY ANIMAL TYPE |
37. 6.34 SPAIN MARKET ANALYSIS BY THERAPEUTIC CLASS |
38. 6.35 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY ANIMAL TYPE |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC CLASS |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY APPLICATION |
45. 6.42 CHINA MARKET ANALYSIS BY ANIMAL TYPE |
46. 6.43 CHINA MARKET ANALYSIS BY THERAPEUTIC CLASS |
47. 6.44 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
48. 6.45 INDIA MARKET ANALYSIS BY APPLICATION |
49. 6.46 INDIA MARKET ANALYSIS BY ANIMAL TYPE |
50. 6.47 INDIA MARKET ANALYSIS BY THERAPEUTIC CLASS |
51. 6.48 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
52. 6.49 JAPAN MARKET ANALYSIS BY APPLICATION |
53. 6.50 JAPAN MARKET ANALYSIS BY ANIMAL TYPE |
54. 6.51 JAPAN MARKET ANALYSIS BY THERAPEUTIC CLASS |
55. 6.52 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY ANIMAL TYPE |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC CLASS |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
60. 6.57 MALAYSIA MARKET ANALYSIS BY APPLICATION |
61. 6.58 MALAYSIA MARKET ANALYSIS BY ANIMAL TYPE |
62. 6.59 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC CLASS |
63. 6.60 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
64. 6.61 THAILAND MARKET ANALYSIS BY APPLICATION |
65. 6.62 THAILAND MARKET ANALYSIS BY ANIMAL TYPE |
66. 6.63 THAILAND MARKET ANALYSIS BY THERAPEUTIC CLASS |
67. 6.64 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
68. 6.65 INDONESIA MARKET ANALYSIS BY APPLICATION |
69. 6.66 INDONESIA MARKET ANALYSIS BY ANIMAL TYPE |
70. 6.67 INDONESIA MARKET ANALYSIS BY THERAPEUTIC CLASS |
71. 6.68 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
72. 6.69 REST OF APAC MARKET ANALYSIS BY APPLICATION |
73. 6.70 REST OF APAC MARKET ANALYSIS BY ANIMAL TYPE |
74. 6.71 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC CLASS |
75. 6.72 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY APPLICATION |
78. 6.75 BRAZIL MARKET ANALYSIS BY ANIMAL TYPE |
79. 6.76 BRAZIL MARKET ANALYSIS BY THERAPEUTIC CLASS |
80. 6.77 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
81. 6.78 MEXICO MARKET ANALYSIS BY APPLICATION |
82. 6.79 MEXICO MARKET ANALYSIS BY ANIMAL TYPE |
83. 6.80 MEXICO MARKET ANALYSIS BY THERAPEUTIC CLASS |
84. 6.81 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
85. 6.82 ARGENTINA MARKET ANALYSIS BY APPLICATION |
86. 6.83 ARGENTINA MARKET ANALYSIS BY ANIMAL TYPE |
87. 6.84 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC CLASS |
88. 6.85 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ANIMAL TYPE |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC CLASS |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY ANIMAL TYPE |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC CLASS |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY ANIMAL TYPE |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC CLASS |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
102. 6.99 REST OF MEA MARKET ANALYSIS BY APPLICATION |
103. 6.100 REST OF MEA MARKET ANALYSIS BY ANIMAL TYPE |
104. 6.101 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC CLASS |
105. 6.102 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY ANIMAL TYPE, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY ANIMAL TYPE, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY THERAPEUTIC CLASS, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY THERAPEUTIC CLASS, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Veterinary Infectious Disease Therapeutic Market Segmentation

Veterinary Infectious Disease Therapeutic Market By Application (USD Billion, 2025-2035)

Bacterial Infections
Viral Infections
Fungal Infections
Parasitic Infections

Veterinary Infectious Disease Therapeutic Market By Animal Type (USD Billion, 2025-2035)

Companion Animals
Livestock
Pets
Equine

Veterinary Infectious Disease Therapeutic Market By Therapeutic Class (USD Billion, 2025-2035)

Antibiotics
Vaccines
Antiparasitics
Antifungals

Veterinary Infectious Disease Therapeutic Market By Route of Administration (USD Billion, 2025-2035)

Oral
Injectable
Topical

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035